Description

How This Works

CJC-1295 (no DAC) is a modified GHRH analog (tetrasubstituted 29-amino acid peptide) that stimulates pulsatile GH release from the pituitary^[1]. Human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 with subcutaneous administration^[1]. Ipamorelin is a pentapeptide GH secretagogue with a half-life of approximately 1.5–2.5 hours^[5] that elicits a rapid GH pulse peaking around 40 minutes post-dose^[6]. Importantly, Ipamorelin selectively increases GH without affecting ACTH, cortisol, or prolactin levels^[3]. When combined, these peptides may produce synergistic GH release by acting on complementary receptor pathways^[4].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

• Supports sustained GH and IGF-1 elevation through pulsatile release patterns^[1][2].
• Ipamorelin demonstrates selective GH release without cortisol or ACTH elevation^[3].
• Once-daily dosing of CJC-1295 (no DAC) has been shown to normalize growth in animal models^[2].
• Generally well tolerated; possible transient effects may include flushing, headache, or injection-site reactions.
• Some individuals report increased appetite, water retention, or tingling sensations.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, protein-forward diet tailored to energy needs.
• Combine resistance training and aerobic activity to reinforce metabolic adaptations.
• Prioritize sleep quality, as GH is predominantly released during deep sleep.
• Manage stress to support optimal hormonal balance and recovery.